Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment

2022; Elsevier BV; Volume: 21; Issue: 9 Linguagem: Inglês

10.1016/j.cgh.2022.11.029

ISSN

1542-7714

Autores

Edward V. Loftus, Jean–Fréderic Colombel, Ken Takeuchi, Xiang Gao, Remo Panaccione, Silvio Danese, Marla C. Dubinsky, Stefan Schreiber, Dapo Ilo, Tricia Finney‐Hayward, Wen Zhou, Charles D. Phillips, Yuri Sánchez González, Lei Shu, Xuan Yao, Qing Zhou, Séverine Vermeire,

Tópico(s)

Liver Disease Diagnosis and Treatment

Resumo

BACKGROUND & AIMS:We evaluated the efficacy of once-daily (QD) upadacitinib 45 mg, an oral, reversible Janus kinase inhibitor, on early symptomatic improvement for ulcerative colitis (UC).Post hoc analysesAbbreviations used in this paper: CI, confidence interval; COVID-19, coronavirus disease 2019; FCP, fecal calprotectin; HRQoL, health-related quality of life; hs-CRP, high-sensitivity C-reactive protein; JAK, Janus kinase; MWPC, meaningful within-patient change; OR, odds ratio; PRO,

Referência(s)